<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2215-3470</journal-id>
<journal-title><![CDATA[Uniciencia]]></journal-title>
<abbrev-journal-title><![CDATA[Uniciencia]]></abbrev-journal-title>
<issn>2215-3470</issn>
<publisher>
<publisher-name><![CDATA[Universidad Nacional, Costa Rica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2215-34702022000100687</article-id>
<article-id pub-id-type="doi">10.15359/ru.36-1.44</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[La vía de los esfingolípidos como biosensor de la quimiosensibilidad al cáncer: Una prueba de principio]]></article-title>
<article-title xml:lang="en"><![CDATA[Sphingolipid pathway as a biosensor of cancer chemosensitivity: a proof of principle]]></article-title>
<article-title xml:lang="pt"><![CDATA[A via dos esfingolipídeos como biossensor da quimiossensibilidade do câncer: Uma prova de princípio]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Molina-Mora]]></surname>
<given-names><![CDATA[José Arturo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mesen-Porras]]></surname>
<given-names><![CDATA[Susana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Quirós-Fernández]]></surname>
<given-names><![CDATA[Isaac]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Kop-Montero]]></surname>
<given-names><![CDATA[Mariana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rojas-Céspedes]]></surname>
<given-names><![CDATA[Andrea]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Quirós]]></surname>
<given-names><![CDATA[Steve]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Siles]]></surname>
<given-names><![CDATA[Francisco]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mora]]></surname>
<given-names><![CDATA[Rodrigo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,University of Costa Rica Faculty of Microbiology Research Center on Tropical Diseases (CIET)]]></institution>
<addr-line><![CDATA[San José ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,University of Costa Rica Faculty of Microbiology Research Center on Tropical Diseases (CIET)]]></institution>
<addr-line><![CDATA[San José ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,University of Costa Rica Faculty of Microbiology Research Center on Tropical Diseases (CIET)]]></institution>
<addr-line><![CDATA[San José ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,University of Costa Rica Faculty of Microbiology Research Center on Tropical Diseases (CIET)]]></institution>
<addr-line><![CDATA[San José ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,University of Costa Rica Faculty of Microbiology Research Center on Tropical Diseases (CIET)]]></institution>
<addr-line><![CDATA[San José ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,University of Costa Rica Faculty of Microbiology Research Center on Tropical Diseases (CIET)]]></institution>
<addr-line><![CDATA[San José ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af7">
<institution><![CDATA[,University of Costa Rica Faculty of Engineering PRIS-LAB School of Electrical Engineering]]></institution>
<addr-line><![CDATA[San José ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af8">
<institution><![CDATA[,University of Costa Rica Faculty of Microbiology Research Center on Tropical Diseases (CIET)]]></institution>
<addr-line><![CDATA[San José ]]></addr-line>
<country>Costa Rica</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<volume>36</volume>
<numero>1</numero>
<fpage>687</fpage>
<lpage>701</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_arttext&amp;pid=S2215-34702022000100687&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_abstract&amp;pid=S2215-34702022000100687&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_pdf&amp;pid=S2215-34702022000100687&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El cáncer es una enfermedad genética compleja con opciones terapéuticas limitadas, debido a la heterogeneidad tumoral y a la aparición de multirresistencia a los fármacos. La vía metabólica de los esfingolípidos (SL) se caracteriza por ser capaz de integrar diferentes tipos de señales de estrés celular y definir la supervivencia celular. Por lo tanto, sugerimos estudiar las perturbaciones en la vía de los esfingolípidos (SLP) causadas por fármacos quimioterapéuticos utilizando un enfoque de biología de sistemas y evaluar su funcionalidad como sensor de respuesta a fármacos. Usamos un sensor de esfingomielina-BODIPY (SMBOD) para estudiar el metabolismo de SL mediante citometría de flujo e imágenes de células vivas en diferentes modelos de cáncer. Para decodificar la complejidad de la ruta, implementamos modelos de mezcla gaussianos, modelos de ecuaciones diferenciales ordinarias, algoritmos de clasificación no supervisados y un modelo de lógica difusa para evaluar su utilidad como sensor de respuesta a la quimioterapia. Nuestros resultados muestran que los fármacos quimioterapéuticos perturban la SLP de diferentes formas y de una manera específica de la línea celular. Además, encontramos que pocas características de fluorescencia de SM-BOD predicen la quimiosensibilidad con alta precisión. Finalmente, encontramos que la composición relativa de especies de SL parece contribuir a la citotoxicidad resultante de muchos tratamientos. Este informe ofrece un marco conceptual y matemático para desarrollar modelos matemáticos personalizados para predecir y mejorar la terapia del cáncer.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Cancer is a complex genetic disease with reduced treatment alternatives due to tumor heterogeneity and drug multiresistance emergence. The sphingolipid (SL) metabolic pathway integrates different responses of cellular stress signals and defines cell survival. Therefore, we suggest studying the perturbations on the sphingolipid pathway (SLP) caused by chemotherapeutic drugs using a systems biology approach to evaluate its functionality as a drug response sensor. We used a sphingomyelin-BODIPY (SM-BOD) sensor to study SL metabolism by flow cytometry and live cell imaging in different cancer models. To decode pathway complexity, we implemented Gussian mixture models, ordinary differential equations models, unsupervised classification algorithms and a fuzzy logic approach to assess its utility as a chemotherapy response sensor. Our results show that chemotherapeutic drugs perturb the SLP in different ways in a cell line-specific manner. In addition, we found that few SM-BOD fluorescence features predict chemosensitivity with high accuracy. Finally, we found that the relative species composition of SL appears to contribute to the resulting cytotoxicity of many treatments. This report offers a conceptual and mathematical framework for developing personalized mathematical models to predict and improve cancer therapy.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo O câncer é uma doença genética complexa com opções terapêuticas limitadas, devido à heterogeneidade tumoral e ao aparecimento de multirresistência aos fármacos. A via metabólica dos esfingolipídeos (SP) é caracterizada por ser capaz de integrar diferentes tipos de sinais de estresse celular e definir a sobrevivência celular. Portanto, sugerimos estudar as perturbações na rota dos esfingolipídeos (SP) causadas por fármacos quimioterápicos usando uma abordagem de biologia de sistemas e avaliar sua funcionalidade como sensor de resposta a fármacos. Usamos um sensor de esfingomielina-BODIPY (SM-BOD) para estudar o metabolismo do SP por citometria de fluxo e imagens de células vivas em diferentes modelos de câncer. Para decodificar a complexidade do caminho, implementamos modelos de mistura gaussiana, modelos de equações diferenciais ordinárias, algoritmos de classificação não supervisionados e um modelo de lógica difusa para avaliar sua utilidade como sensor de resposta à quimioterapia. Nossos resultados mostram que os fármacos quimioterápicos perturbam a rota dos SP de diferentes maneiras e de maneira específica da linhagem celular. Além disso, descobrimos que poucas características de fluorescência do SM-BOD predizem a quimiossensibilidade com alta precisão. Finalmente, descobrimos que a composição relativa de espécies de SP parece contribuir para a citotoxicidade resultante de muitos tratamentos. Este relatório oferece uma estrutura conceitual e matemática para o desenvolvimento de modelos matemáticos personalizados para prever e melhorar a terapia do câncer.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[cancer]]></kwd>
<kwd lng="en"><![CDATA[tumor chemosensitivity]]></kwd>
<kwd lng="en"><![CDATA[sphingolipids]]></kwd>
<kwd lng="en"><![CDATA[systems biology]]></kwd>
<kwd lng="en"><![CDATA[chemotherapy]]></kwd>
<kwd lng="en"><![CDATA[fuzzy logic.]]></kwd>
<kwd lng="es"><![CDATA[Cáncer]]></kwd>
<kwd lng="es"><![CDATA[quimiosensibilidad tumoral]]></kwd>
<kwd lng="es"><![CDATA[esfingolípidos]]></kwd>
<kwd lng="es"><![CDATA[biología de sistemas]]></kwd>
<kwd lng="es"><![CDATA[quimioterapia]]></kwd>
<kwd lng="es"><![CDATA[lógica difusa.]]></kwd>
<kwd lng="pt"><![CDATA[Câncer]]></kwd>
<kwd lng="pt"><![CDATA[quimiossensibilidade do tumor]]></kwd>
<kwd lng="pt"><![CDATA[esfingolipídeos]]></kwd>
<kwd lng="pt"><![CDATA[biologia de sistemas]]></kwd>
<kwd lng="pt"><![CDATA[quimioterapia]]></kwd>
<kwd lng="pt"><![CDATA[lógica difusa]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al Daoud]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Daoud]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer Diagnosis Using Modified Fuzzy Network.]]></article-title>
<source><![CDATA[Universal Journal of Computer Science and Engineering Technology]]></source>
<year>2010</year>
<volume>1</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>73-8</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barteneva]]></surname>
<given-names><![CDATA[N. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Fasler-Kan]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Vorobjev]]></surname>
<given-names><![CDATA[I. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Imaging flow cytometry: coping with heterogeneity in biological systems.]]></article-title>
<source><![CDATA[The Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society]]></source>
<year>2012</year>
<volume>60</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>723-33</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bensimon]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Heck]]></surname>
<given-names><![CDATA[A. J. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Aebersold]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mass spectrometry-based proteomics and network biology.]]></article-title>
<source><![CDATA[Annual Review of Biochemistry]]></source>
<year>2012</year>
<volume>81</volume>
<page-range>379-405</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bonhoure]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Pchejetski]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Aouali]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Morjani]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Levade]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Kohama]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Cuvillier]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1.]]></article-title>
<source><![CDATA[Leukemia]]></source>
<year>2006</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>95-102</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bosl]]></surname>
<given-names><![CDATA[W. J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systems biology by the rules: hybrid intelligent systems for pathway modeling and discovery.]]></article-title>
<source><![CDATA[BMC Systems Biology]]></source>
<year>2007</year>
<volume>1</volume>
<page-range>13</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chai]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[McLaren]]></surname>
<given-names><![CDATA[R. P.]]></given-names>
</name>
<name>
<surname><![CDATA[Byrne]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Chuang]]></surname>
<given-names><![CDATA[W. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Dufault]]></surname>
<given-names><![CDATA[M. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[Y. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The chemosensitizing activity of inhibitors of glucosylceramide synthase is mediated primarily through modulation of P-gp function.]]></article-title>
<source><![CDATA[International Journal of Oncology]]></source>
<year>2011</year>
<volume>38</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>701-11</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[Chuan]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[Caibo]]></given-names>
</name>
<name>
<surname><![CDATA[Yarden]]></surname>
<given-names><![CDATA[Yosef]]></given-names>
</name>
<name>
<surname><![CDATA[K.W.To]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Fu.]]></surname>
<given-names><![CDATA[Liwu]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The prospects of tumor chemosensitivity testing at the single-cell level.]]></article-title>
<source><![CDATA[Drug Resistance Updates]]></source>
<year>2021</year>
<volume>54</volume>
</nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dupre]]></surname>
<given-names><![CDATA[T. V.]]></given-names>
</name>
<name>
<surname><![CDATA[Doll]]></surname>
<given-names><![CDATA[M. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[P. P.]]></given-names>
</name>
<name>
<surname><![CDATA[Sharp]]></surname>
<given-names><![CDATA[C. N.]]></given-names>
</name>
<name>
<surname><![CDATA[Siow]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Megyesi]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Siskind]]></surname>
<given-names><![CDATA[L. J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inhibiting glucosylceramide synthase exacerbates cisplatin-induced acute kidney injury.]]></article-title>
<source><![CDATA[Journal of Lipid Research]]></source>
<year>2017</year>
<volume>58</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1439-52</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dyatlovitskaya]]></surname>
<given-names><![CDATA[E. V.]]></given-names>
</name>
<name>
<surname><![CDATA[Kandyba]]></surname>
<given-names><![CDATA[A. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Kozlov]]></surname>
<given-names><![CDATA[A. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Somova]]></surname>
<given-names><![CDATA[O. G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sphinganine in sphingomyelins of tumors and mouse regenerating liver.]]></article-title>
<source><![CDATA[Biochemistry (Moscow)]]></source>
<year>2001</year>
<volume>66</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>502-4</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Erlich]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Miranda]]></surname>
<given-names><![CDATA[S. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Visser]]></surname>
<given-names><![CDATA[J. W.]]></given-names>
</name>
<name>
<surname><![CDATA[Dagan]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Gatt]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Schuchman]]></surname>
<given-names><![CDATA[E. H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fluorescence-based selection of gene-corrected hematopoietic stem and progenitor cells from acid sphingomyelinase-deficient mice: implications for Niemann-Pick disease gene therapy and the development of improved stem cell gene transfer procedures.]]></article-title>
<source><![CDATA[Blood]]></source>
<year>1999</year>
<volume>93</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>80-6</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernandis]]></surname>
<given-names><![CDATA[A. Z.]]></given-names>
</name>
<name>
<surname><![CDATA[Wenk]]></surname>
<given-names><![CDATA[M. R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lipid-based biomarkers for cancer.]]></article-title>
<source><![CDATA[Journal of Chromatography B]]></source>
<year>2009</year>
<volume>877</volume>
<numero>26</numero>
<issue>26</issue>
<page-range>2830-5</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Glaysher]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Cree]]></surname>
<given-names><![CDATA[I. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cell Sensitivity Assays: The ATP-based Tumor Chemosensitivity Assay.]]></article-title>
<source><![CDATA[Methods in molecular biology]]></source>
<year>2011</year>
<volume>731</volume>
<page-range>247-57</page-range><publisher-loc><![CDATA[Clifton, N.J ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guillermet-Guibert]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Davenne]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Pchejetski]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Saint-Laurent]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Brizuela]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Guilbeau-Frugier]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug.]]></article-title>
<source><![CDATA[Molecular Cancer Therapeutics]]></source>
<year>2009</year>
<volume>8</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>809-20</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hannun]]></surname>
<given-names><![CDATA[Y. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Obeid]]></surname>
<given-names><![CDATA[L. M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Principles of bioactive lipid signalling: Lessons from sphingolipids.]]></article-title>
<source><![CDATA[Nature Reviews Molecular Cell Biology]]></source>
<year>2008</year>
<volume>9</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>139-50</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iessi]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Marconi]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Manganelli]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Sorice]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Malorni]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Garofalo]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Matarrese]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[On the role of sphingolipids in cell survival and death.]]></article-title>
<source><![CDATA[International Review of Cell and Molecular Biology]]></source>
<year>2020</year>
<volume>1</volume>
<numero>351</numero>
<issue>351</issue>
</nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kenchegowda]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Rahamathulla]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Hani]]></surname>
<given-names><![CDATA[U.]]></given-names>
</name>
<name>
<surname><![CDATA[Begum]]></surname>
<given-names><![CDATA[M. Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Guruswamy]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Osmani]]></surname>
<given-names><![CDATA[R. A. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Gowda]]></surname>
<given-names><![CDATA[D. V.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Smart Nanocarriers as an Emerging Platform for Cancer Therapy: A Review.]]></article-title>
<source><![CDATA[Molecules]]></source>
<year>2022</year>
<volume>27</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kitano]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cáncer as a robust system: Implications for anticancer therapy.]]></article-title>
<source><![CDATA[Nature Reviews Cáncer]]></source>
<year>2004</year>
<volume>4</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>227-35</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Koval]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Pagano]]></surname>
<given-names><![CDATA[R. E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intracellular transport and metabolism of sphingomyelin.]]></article-title>
<source><![CDATA[Biochimica et Biophysica Acta]]></source>
<year>1991</year>
<volume>1082</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>113-25</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kroll]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[H. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[M. H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antineoplastic Agents Targeting Sphingolipid Pathways.]]></article-title>
<source><![CDATA[Frontiers in Oncology]]></source>
<year>2020</year>
<volume>10</volume>
<page-range>833</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lacour]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Hammann]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Grazide]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Lagadic-Gossmann]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Athias]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Sergent]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Dimanche-Boitrel]]></surname>
<given-names><![CDATA[M. T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells.]]></article-title>
<source><![CDATA[Cancer Research]]></source>
<year>2004</year>
<volume>64</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>3593-8</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lippert]]></surname>
<given-names><![CDATA[T. H.]]></given-names>
</name>
<name>
<surname><![CDATA[Ruoff]]></surname>
<given-names><![CDATA[H. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Volm]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intrinsic and acquired drug resistance in malignant tumors.]]></article-title>
<source><![CDATA[The main reason for therapeutic failure]]></source>
<year>2008</year>
<volume>58</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>261-4</page-range><publisher-name><![CDATA[Arzneimittel-Forschung]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lukow]]></surname>
<given-names><![CDATA[D. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Sheltzer]]></surname>
<given-names><![CDATA[J. M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chromosomal instability and aneuploidy as causes of cancer drug resistance.]]></article-title>
<source><![CDATA[Trends in Cancer]]></source>
<year>2021</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>43-53</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Machala]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Procházková]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Hofmanová]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Králiková]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Slavík]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Tylichová]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
<name>
<surname><![CDATA[Vondrá&#269;ek]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Colon cancer and perturbations of the sphingolipid metabolism.]]></article-title>
<source><![CDATA[International Journal of Molecular Sciences]]></source>
<year>2019</year>
<volume>20</volume>
<numero>23</numero>
<issue>23</issue>
</nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Molina-Mora]]></surname>
<given-names><![CDATA[J. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Kop-Montero]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Quirós-Fernández]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Quirós]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Crespo-Mariño]]></surname>
<given-names><![CDATA[J. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Mora-Rodríguez]]></surname>
<given-names><![CDATA[R. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A hybrid mathematical modeling approach of the metabolic fate of a fluorescent sphingolipid analogue to predict cancer chemosensitivity.]]></article-title>
<source><![CDATA[Computers in Biology and Medicine]]></source>
<year>2018</year>
<volume>97</volume>
<page-range>8-20</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Molina-Mora]]></surname>
<given-names><![CDATA[J. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Mora-Rodríguez]]></surname>
<given-names><![CDATA[R. A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Identification of cancer chemosensitivity by ODE and GMM modeling of heterogeneous cellular response to perturbations in fluorescent sphingolipid metabolism. 2016]]></source>
<year>2016</year>
<conf-name><![CDATA[ IEEE 36th Central American and Panama Convention]]></conf-name>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Molino]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Tate]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[McKillop]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Medin]]></surname>
<given-names><![CDATA[J. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sphingolipid pathway enzymes modulate cell fate and immune responses.]]></article-title>
<source><![CDATA[Immunotherapy]]></source>
<year>2017</year>
<volume>9</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>1185-98</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mora-Rodríguez]]></surname>
<given-names><![CDATA[R. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Molina-Mora]]></surname>
<given-names><![CDATA[J. A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Characterization of heterogeneous response to chemotherapy by perturbation-based modeling of fluorescent sphingolipid metabolism in cancer cell subpopulations.]]></source>
<year>2017</year>
<conf-name><![CDATA[ IEEE 36th Central American and Panama Convention]]></conf-name>
<conf-date>2016</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mora]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Dokic]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Kees]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Hüber]]></surname>
<given-names><![CDATA[C. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Keitel]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Geibig]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Régnier-Vigouroux]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sphingolipid rheostat alterations related to transformation can be exploited for specific induction of lysosomal cell death in murine and human glioma.]]></article-title>
<source><![CDATA[Glia]]></source>
<year>2010</year>
<volume>58</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1364-83</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morales]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Goñi]]></surname>
<given-names><![CDATA[F. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Kolesnick]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-Checa]]></surname>
<given-names><![CDATA[J. C.]]></given-names>
</name>
</person-group>
<source><![CDATA[Sphingolipids and cell death]]></source>
<year>2007</year>
<volume>12</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>923-39</page-range><publisher-name><![CDATA[Apoptosis]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ogretmen]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sphingolipids in cancer: Regulation of pathogenesis and therapy.]]></article-title>
<source><![CDATA[FEBS Letters]]></source>
<year>2006</year>
<volume>580</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>5467-76</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ogretmen]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sphingolipid metabolism in cancer signalling and therapy.]]></article-title>
<source><![CDATA[Nature Reviews Cancer]]></source>
<year>2017</year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>33-50</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quirós-Fernández]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Molina-Mora]]></surname>
<given-names><![CDATA[J. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Kop-Monteo]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Salas-Hidalgo]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Mora-Rodríguez]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<source><![CDATA[Predicting cancer chemosensitivity based on intensity/distribution profiles of cells loaded with a fluorescent sphingolipid analogue.]]></source>
<year>2018</year>
<conf-name><![CDATA[ IEEE International Work Conference on Bioinspired Intelligence (IWOBI)]]></conf-name>
<conf-date>2018</conf-date>
<conf-loc> </conf-loc>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[D. K.]]></given-names>
</name>
<name>
<surname><![CDATA[Ku]]></surname>
<given-names><![CDATA[C. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Wichaidit]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Steininger]]></surname>
<given-names><![CDATA[R. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[L. F.]]></given-names>
</name>
<name>
<surname><![CDATA[Altschuler]]></surname>
<given-names><![CDATA[S. J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patterns of basal signaling heterogeneity can distinguish cellular populations with different drug sensitivities.]]></article-title>
<source><![CDATA[Molecular Systems Biology]]></source>
<year>2010</year>
<volume>6</volume>
<numero>369</numero>
<issue>369</issue>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[R. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Marks]]></surname>
<given-names><![CDATA[D. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Pagano]]></surname>
<given-names><![CDATA[R. E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Using fluorescent sphingolipid analogs to study intracellular lipid trafficking.]]></article-title>
<source><![CDATA[Current Protocols in Cell Biology. Board]]></source>
<year>2007</year>
</nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Slack]]></surname>
<given-names><![CDATA[M. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[E. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[L. F.]]></given-names>
</name>
<name>
<surname><![CDATA[Altschuler]]></surname>
<given-names><![CDATA[S. J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characterizing heterogeneous cellular responses to perturbations.]]></article-title>
<source><![CDATA[Proceedings of the National Academy of Sciences of the United States of America]]></source>
<year>2008</year>
<volume>105</volume>
<numero>49</numero>
<issue>49</issue>
<page-range>19306-11</page-range></nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Solomonov]]></surname>
<given-names><![CDATA[A. V.]]></given-names>
</name>
<name>
<surname><![CDATA[Rumyantsev]]></surname>
<given-names><![CDATA[E. V.]]></given-names>
</name>
<name>
<surname><![CDATA[Kochergin]]></surname>
<given-names><![CDATA[B. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Antina]]></surname>
<given-names><![CDATA[E. V.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Interaction of BODIPY with bovine serum albumin and its bilirubin complex.]]></article-title>
<source><![CDATA[Biophysics]]></source>
<year>2014</year>
<volume>59</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>35-42</page-range></nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tepper]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Ruurs]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Wiedmer]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Sims]]></surname>
<given-names><![CDATA[P. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Borst]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Van Blitterswijk]]></surname>
<given-names><![CDATA[W. J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sphingomyelin hydrolysis to ceramide during the execution phase of apoptosis results from phospholipid scrambling and alters cell-surface morphology.]]></article-title>
<source><![CDATA[Journal of Cell Biology]]></source>
<year>2000</year>
<volume>150</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>155-64</page-range></nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torshabi]]></surname>
<given-names><![CDATA[A. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Riboldi]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Fooladi]]></surname>
<given-names><![CDATA[A. A. I.]]></given-names>
</name>
<name>
<surname><![CDATA[Mosalla]]></surname>
<given-names><![CDATA[S. M. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Baroni]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An adaptive fuzzy prediction model for real time tumor tracking in radiotherapy via external surrogates.]]></article-title>
<source><![CDATA[Journal of Applied Clinical Medical Physics]]></source>
<year>2013</year>
<volume>14</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>102-14</page-range></nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Truman]]></surname>
<given-names><![CDATA[J. P.]]></given-names>
</name>
<name>
<surname><![CDATA[García-Barros]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Obeid]]></surname>
<given-names><![CDATA[L. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Hannun]]></surname>
<given-names><![CDATA[Y. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evolving concepts in cancer therapy through targeting sphingolipid metabolism.]]></article-title>
<source><![CDATA[Biochimica et Biophysica Acta Molecular and Cell Biology of Lipids,]]></source>
<year>2014</year>
<volume>1841</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1174-88</page-range></nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Meer]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Wolthoorn]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Degroote]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The fate and function of glycosphingolipid glucosylceramide.]]></article-title>
<source><![CDATA[Philosophical Transactions of the Royal Society B: Biological Sciences]]></source>
<year>2003</year>
<volume>358</volume>
<numero>1433</numero>
<issue>1433</issue>
<page-range>869-73</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
